BeStock  
Stocks › Biotechnology › CORT

Corcept Therapeutics CORT

US equityMarket cap rank #1733Biotechnology
$63.62 −$1.36 (-2.09%)
Market closed · Nov 20, 8:10 pm ET · Last extended-hours $63.62 0.00%
Open$64.07
Prev close$64.98
Day range$62.81 – $65.13
Volume1.09M
Market cap$6.96B
P/E (TTM)47.8
Dividend yield–

Ownership & positioning

Who holds it, who is betting against it, and where the big money is moving

Institutional ownership74.2%-0.06 pts vs. prior quarter
Institutions holding584-2 vs. prior quarter
Insider trades (recent)10 buys / 35 sellsNet selling
Short interest8.44% of floatDays to cover 8.1 · as of 30 Oct 2026
Short-sale volume share15.3%5-day average of daily volume

Short-sale volume as % of daily volume

8%12%17%21%Oct '26Oct '26Nov '26

Large-order net flow, last 20 sessions

Net of large-order buying minus selling, in USD. Over this window: −$14.66M (5 inflow days, 15 outflow days).

Net flow by order size, last 20 sessions

+$1.6MSuper−$16.2MBig−$880.5KMid−$5.0MSmall

Super/Big orders approximate institutional-size trades; Mid/Small approximate retail-size trades. Net buy minus sell value in each bucket, summed over the window.

The five largest holders on file together own 30.4% of shares outstanding.

Largest holders

  • BlackRock9.32%
  • Ingalls & Snyder, LLC7.01%
  • George Baker5.07%
  • Vanguard Capital Management, LLC4.54%
  • Renaissance Technologies Corp.4.43%
  • Vanguard Portfolio Management, LLC4.36%
  • Parallel Advisors, LLC3.57%
  • AQR Capital Management3.29%

By investor type

  • Mutual Fund56.75%
  • Hedge Fund12.04%
  • Individual/Insider10.54%
  • Private Company1.66%
  • Public Company1.33%
  • Government Pension Fund1.06%
  • Sovereign Wealth Fund0.45%
  • VC/PE Fund0.41%

Reported short interest has fallen from 8.97% to 8.44% of float over the last 6 biweekly reports (14 Aug 2026 to 30 Oct 2026).

Recent institutional activity

HolderTypePeriodShare changeNew stake
D. E. Shaw & Co., L.P. Hedge Fund 2026/Q4 +1,041,272 1.8%
AQR Capital Management Hedge Fund 2026/Q4 +1,038,815 3.3%
Jane Street Group, LLC Private Company 2026/Q4 +757,074 0.7%
Federated Hermes, Inc. Mutual Fund 2026/Q4 +421,742 0.4%
Two Sigma Investments, LP Hedge Fund 2026/Q4 +295,600 0.8%
Hudson River Trading LLC Private Company 2026/Q4 +271,149 0.4%
Barclays PLC Public Company 2026/Q4 +244,925 0.3%
Bridgewater Associates Hedge Fund 2026/Q4 +210,578 0.2%
Vanguard Capital Management, LLC Mutual Fund 2026/Q4 +185,080 4.5%
T. Rowe Price Group, Inc. Mutual Fund 2026/Q4 +165,998 0.3%
FMR Mutual Fund 2026/Q4 +151,025 3.2%
California Public Employees' Retirement System Government Pension Fund 2026/Q4 +139,533 0.1%
Citadel Advisors LLC Hedge Fund 2026/Q4 +130,713 0.2%
Northern Trust Global Investments Mutual Fund 2026/Q4 +123,995 0.8%
Jacobs Levy Equity Management Inc Mutual Fund 2026/Q4 +106,926 0.7%

Institutional buy/sell activity by reporting period, largest moves first.

Insider transactions

DateInsiderTitleTransactionSharesPriceHeld after
9 Nov 2026 Daniel Swisher Independent Director Derivative Exercise and Sale -1,500 $74.07 –
2 Nov 2026 Sean Maduck Former President of Endocrinology Derivative Exercise and Sale -25,000 $82.68 129,593
1 Nov 2026 Roberto Vieira President of Oncology Derivative Exercise and Sale -8,333 $81.52 3,946
14 Oct 2026 James Wilson Independent Chairperson Automatic Disposition -10,000 $116.30 1,454,543
1 Oct 2026 Roberto Vieira President of Oncology Derivative Exercise and Sale -8,333 $116.59 3,946
1 Oct 2026 Sean Maduck Former President of Endocrinology Derivative Exercise and Sale -25,000 $116.55 119,655
1 Oct 2026 Joseph Lyon Chief Technology & Accounting Officer Derivative Exercise and Sale -10,000 $116.54 5,683
30 Sep 2026 Joseph Lyon Chief Technology & Accounting Officer Intent to Sell (Form 144) -10,000 $115.23 –
30 Sep 2026 Justin Gunn President of Endocrinology Other Derivative Acquisition +100,000 $114.03 100,000
30 Sep 2026 Justin Gunn President of Endocrinology Initial Statement of Beneficial +0 – 6,965
23 Sep 2026 Gary Robb Chief Business Officer & Secretary Other Acquisition +10,000 – 94,914
23 Sep 2026 Gary Robb Chief Business Officer & Secretary Other Disposition -17,100 – 94,914
16 Sep 2026 Gary Robb Chief Business Officer & Secretary Derivative Exercise and Retained +17,493 $8.27 102,014
15 Sep 2026 Roberto Vieira President of Oncology Automatic Disposition -296 $100.82 3,946
14 Sep 2026 James Wilson Independent Chairperson Automatic Disposition -10,000 $111.70 1,464,543
13 Sep 2026 Joseph Lyon Chief Technology & Accounting Officer Derivative Exercise and Sale -10,000 $114.12 5,683
1 Sep 2026 Atabak Mokari Chief Financial Officer Sale to Issuer -102 $113.38 16,304
1 Sep 2026 Gary Robb Chief Business Officer & Secretary Sale to Issuer -91 $113.38 84,521
1 Sep 2026 Sean Maduck Former President of Endocrinology Sale to Issuer -117 $113.38 119,655
1 Sep 2026 Joseph Lyon Chief Technology & Accounting Officer Sale to Issuer -72 $113.38 5,683

From Form 4/Form 144 filings. Negative share counts are disposals (sales, gifts, or shares withheld for taxes); positive are acquisitions.

Short interest, by report

Report dateShares short% of floatDays to cover
30 Oct 2026 9,125,717 8.4% 8.1
15 Oct 2026 8,588,418 7.9% 12.3
30 Sep 2026 8,540,393 7.9% 3.6
15 Sep 2026 9,350,914 8.7% 9.9
31 Aug 2026 9,399,154 8.7% 11.9
14 Aug 2026 9,696,757 9.0% 10.5

Discussion

No comments yet — be the first to weigh in on CORT.

Sign in to join the discussion.

Scroll to Top